about
sameAs
NeuroblastomaDihydroceramides: From Bit Players to Lead ActorsTamoxifen regulation of sphingolipid metabolism--Therapeutic implicationsHeterogeneous role of the glutathione antioxidant system in modulating the response of ESFT to fenretinide in normoxia and hypoxiaDynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemiaNovel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity (PSP)Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma.Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580.Pharmacological inhibition of lipofuscin accumulation in the retina as a therapeutic strategy for dry AMD treatment.Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide.BBC3 mediates fenretinide-induced cell death in neuroblastomaTetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin CSynthesis and preliminary chemotherapeutic evaluation of the fully C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.ERK1/2 deactivation enhances cytoplasmic Nur77 expression level and improves the apoptotic effect of fenretinide in human liver cancer cellsRetinoic acid pathway activity in Wilms tumors and characterization of biological responses in vitro.Mitochondria: redox metabolism and dysfunction.An overview of pharmacological approaches for management and repair of spinal cord injuries.Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells.Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.Bryostatin-1, Fenretinide and 1α,25 (OH)(2)D(3) Induce Growth Inhibition, Apoptosis and Differentiation in T and B Cell-Derived Acute Lymphoblastic Leukemia Cell Lines (CCRF-CEM and Nalm-6)Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice.Preferential eradication of acute myelogenous leukemia stem cells by fenretinide.Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death.Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.Converting redox signaling to apoptotic activities by stress-responsive regulators HSF1 and NRF2 in fenretinide treated cancer cells.Pre-Clinical Evaluation of rHDL Encapsulated Retinoids for the Treatment of Neuroblastoma.Implication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl)retinamide-induced apoptosisClinically Evaluated Cancer Drugs Inhibiting Redox Signaling.Human T-cell lymphotropic virus type I-transformed T-cells have a partial defect in ceramide synthesis in response to N-(4-hydroxyphenyl)retinamideCombination therapies improve the anticancer activities of retinoids in neuroblastoma.A Non-imaging High Throughput Approach to Chemical Library Screening at the Unmodified Adenosine-A3 Receptor in Living Cells.
P2860
Q24617733-09E04231-138C-43D9-B41C-6B6D366A14D9Q26851948-02C87601-A852-4AAD-A016-BA2C8EA82557Q28084270-CE37D8E6-529A-40AF-8A6B-FB8FE25508AEQ28478325-419CE3C5-0872-4855-A456-BEDB0FB6EDE4Q30278944-B6F10F3C-363D-4312-B70F-B79C2584D15BQ30438632-9B9D5F00-729E-4A50-8C14-85F9D3D30C2AQ33257134-B2D482BF-6C5A-4969-90EC-C02C04C95183Q33424045-C41FAF14-9AC0-423C-A4EC-C13A1F4DB744Q33940548-69B46F9E-44AC-4DEE-B58E-98009C0FC37BQ34074393-5DC57599-A648-48A6-8711-4C0039CFD867Q34182665-7CD3E121-1C1E-4F3E-B240-CD728B195F05Q34231949-776BC352-A54D-4523-8E57-1FA20657ED56Q34232178-3D159E84-0996-42B0-85B0-FB9553D9A218Q34601105-03C1ACAB-EA9C-4801-B9AE-C0C6F50F3D2EQ34687273-2CC1F366-981A-451A-AD58-B2E80F9DD875Q35617537-4092FDE7-AF41-4C3F-A263-E3E94E4C86BFQ35944831-A1FD83EC-23CD-4E18-A7CA-9FF71F6DEE9BQ36092501-DE741791-B1EF-4B83-A34B-C08616C7B4DFQ36157119-27C75A85-7F34-450A-BFE0-CC33C9607C5DQ36159154-10950A05-820C-48D2-8CE4-3D92F704390FQ36571416-2A472CFA-8AA1-41DA-9721-677184D8D72CQ36613829-5302AB26-D6FB-406E-8396-097B907957B6Q36747742-837C7458-4231-4C86-BD3B-06A9135712E7Q36874463-E56476F7-3B98-4D6E-840D-7FE221EAFF87Q36924378-9CFCB9FC-FCBD-4EB3-9796-9C706BFF4DDDQ37344577-6D6C702D-E5C0-4C71-9CDE-7602BA30E192Q37383868-54602837-A840-4922-9BBE-E77E2EFBBA97Q37475635-438E7D1D-4AB6-4EBA-97D0-48FCAD806F89Q38283683-5F767953-B0B4-4CCE-9D91-E36710E9CD48Q38777221-D6269831-0106-4ED3-85E5-986CD304FE87Q40387380-85B842AA-16E0-4507-A593-7DB545C02057Q43134812-90A12108-6053-4619-8341-E5B5D51B6C9EQ49714374-61705BB1-FF85-4ADB-A14E-3D31242B4D5B
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Mechanism of fenretinide (4-HPR)-induced cell death
@ast
Mechanism of fenretinide (4-HPR)-induced cell death
@en
Mechanism of fenretinide (4-HPR)-induced cell death
@nl
type
label
Mechanism of fenretinide (4-HPR)-induced cell death
@ast
Mechanism of fenretinide (4-HPR)-induced cell death
@en
Mechanism of fenretinide (4-HPR)-induced cell death
@nl
prefLabel
Mechanism of fenretinide (4-HPR)-induced cell death
@ast
Mechanism of fenretinide (4-HPR)-induced cell death
@en
Mechanism of fenretinide (4-HPR)-induced cell death
@nl
P2093
P356
P1433
P1476
Mechanism of fenretinide (4-HPR)-induced cell death
@en
P2093
A M DiPietrantonio
P2888
P304
P356
10.1023/A:1011342220621
P407
P577
2001-10-01T00:00:00Z
P6179
1034342348